Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (100.43 KB, 1 trang )
TABLE 8.4
NEUROMUSCULAR-BLOCKING AGENTS (PARALYTICS)
Medication
Dose
Succinylcholine
Rocuronium
Vecuronium
Cisatracurium
1–2 mg/kg
0.6–1.2 mg/kg
0.1–0.2 mg/kg
0.1–0.2 mg/kg
Nondepolarizing NMBAs do not cause fasciculations or associated side effects.
Rocuronium is the most frequently used drug from this class for RSI. When used
at higher dose (1.2 mg/kg), it has been shown to achieve equivalent intubating
conditions in the same time frame as succinylcholine. However, it has a duration
of 30 to 45 minutes or longer.
Rocuronium’s longer duration is often cited as a disadvantage. However, newer
considerations make the longer duration an advantage over succinylcholine in
difficult intubations during which the duration of succinylcholine has elapsed,
resulting with the return of muscle tone, movement, and risk of active
regurgitation/aspiration. With rocuronium, paralysis is maintained and the patient
can be bag-mask ventilated for another intubation attempt. Additionally,
maintenance of the paralysis is preferable for imaging, ventilator management,
vascular access, etc. The need for the early reversal of rocuronium paralysis is
occasionally beneficial, either to allow return of spontaneous respiration if
intubation is not successful, or to allow return of a neurologic examination.